

Sixth Regional Symposium on the Design and Methods of Clinical Trials, October 16–17, 1997, San Francisco, CA. Contact: Office of Continuing Medical Education, Registration Office, Room MCB-630, University of California, San Francisco, CA 94143-0742. Phone: (415) 476-5808.

Controlling the Complement System, October 16-17, 1997, Renaissance Washington DC Hotel, Washington, DC. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: inq@ibcusa.com.

Seventeenth International Symposium on the Separation of Proteins, Peptides, and Polynucleotides, October 26-29, 1997, Washington, DC. Contact: Janet Cunningham, Barr Enterprises, P.O. Box 279, Walkersville, MD 21793. Phone: (301) 898-3772; Fax: (301) 898-5596; E-mail: Janetbarr@aol.com.

Fourth Annual Conference on Apoptosis: Therapeutic Strategies for Regulating Cell Death, October 27-28, 1997, Westin Hotel Horton Plaza, San Diego, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: inq@ibcusa.com.

Dana-Farber Cancer Institute's Fiftieth Anniversary Scientific Symposium, October 30-November 1, 1997, Boston, MA. Contact: Professional Meeting Planners, 5 Central Square, Suite 201, Stoneham, MA 02180. Phone: (617) 279-9887 or (800) 378-6857; Fax: (617) 279-9875; E-mail: PMPMeeting@aol.com.

Eighth Annual IBC International Conference on Antibody Engineering: New Technology, Application & Commercialization, December 3-5, 1997, Hotel del Coronado, Coronado, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772-1749. Phone: (508) 481-6400; Fax: (508) 481-7911; E-mail: inq@ibcusa.com.

International Symposium on Metastases in Head and Neck Cancer, January 15-18, 1998, Kiel, Germany. Contact: Dr. J.A. Werner or Dr. B.M. Lippert, Dept. of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Arnold-Heller-Str. 14, D-24105 Kiel, Germany. Phone: 49-431-597-2321; Fax: 49-431-597-2272; E-mail: j.a.werner@t-online.de.

Cardiovascular Health: Coming Together for the 21st Century, February 19-21, 1998, Hyatt Regency Embarcadero, San Francisco, CA. Contact: CORE Program, Attn. Greg Oliva, Department of Health Services, Mail Station #725, P.O. Box 942732, Sacramento, CA 94234-7320. E-mail: goliva@hw1.cahwnet.gov.

Advances in Oncology Nursing, February 20-21, 1998, Houston, TX. Contact: University of Texas M.D. Anderson Cancer Center, Office of Conference Services, Box 131, 1515 Holcombe Boulevard, Houston, TX 77030-4095. Phone: (713) 792-2222; Fax: (713) 794-1724; E-mail: meetings@mdacc.tmc.edu.

Correction

We had previously described the discovery of a naturally occurring but oncogenic variant of a normally benign human papillomavirus (1). In Table 3 of that work, we described what we then believed to be errors in the previously published sequence of the prototype of HPV 11 (HPV 11P) (2). Recent resequencing of both the prototype of HPV 11P as well as the oncogenic variant, HPV 11VC, revealed that several, but not all, of the "errors" attributed to the HPV 11P sequence were actually mutations in the HPV 11VC genome. The C¹⁷⁸³→G, G¹⁷⁸⁴→C, and C⁷⁷¹⁸→CGC changes in the sequence of HPV 11P have been confirmed by resequencing both strands of HPV 11P and HPV 11VC. The nucleotide changes T¹³⁷→C, A¹⁸⁶→C, C³⁸⁰→T, G⁴³¹→A, G⁴⁶⁶→A, G⁶⁶²→T, and C³⁴⁸⁷→T previously reported for the HPV 11P sequence are in fact mutations in the HPV 11VC genome and should have been in Table 4 of R. McGlennen *et al.* (1). While these changes do not alter the significance of our isolation of an oncogenic variant of HPV 11, they do introduce additional amino acid alterations in the E6, E1, and E4 open reading frames that could affect the oncogenic potential of HPV 11VC. We are currently examining the effect of these mutations.

Ronald C. McGlennen
 Jyotsna Ghai
 Ronald S. Ostrow
 Kurt LaBresh
 John F. Schneider
 Anthony J. Faras
 Institute of Human Genetics and
 Department of Microbiology
 University of Minnesota
 Minneapolis, MN 55455

References

1. McGlennen, R., Ghai, J., Ostrow, R., LaBresh, K., Schneider, J., and Faras, A. Cellular transformation by a unique isolate of human papillomavirus type 11. *Cancer Res.*, 52: 5872–5878, 1992.
2. Dartmann, K., Schwartz, E., Gissmann, L., and zur Hausen, H. The nucleotide sequence and genome organization of human papillomavirus type 11. *Virology*, 151: 124–130, 1986.